2015 Annual Meeting | 3HC.001 - Treating the New-onset Epilepsy Patient

Date Monday 04/20/15

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Gregory Krauss, MD

Topic(s)

Learning Objectives Participants should be able to recognize key seizure types and epilepsy syndromes in children, adults, and the elderly; and to appreciate causes of seizures at different ages and risks for seizure recurrence in determining treatment needs. Participants should be able to accurately screen patients at different ages for epilepsy and identify different etiologies and understand their influence on recurrence. Participants should also be aware of clinical trial data on choosing treatments and practical points in managing patients with new-onset epilepsy.

CME Available 3.75 CME credits

Program Tracks Subspecialty in Focus

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
08:00 AM - 08:15 AM		Introduction Gregory Krauss, MD
08:15 AM - 09:00 AM		Population Study of First Seizures and Need for Treatment Gregory K. Bergey, MD, FAAN
09:00 AM - 09:45 AM		New-onset Epilepsy in Children Dave F. Clarke, MD
09:45 AM - 10:00 AM		Break
10:00 AM - 10:45 AM		New-onset Epilepsy in the Elderly Ilo Leppik, MD
10:45 AM - 11:30 AM		Drug Choices and Treatment in New-onset Epilepsy Elinor Ben-Menachem, MD, FAAN
11:30 AM - 12:00 AM		Questions and Answers

Faculty Disclosures
Gregory Krauss, MD	Dr. Krauss has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvelle. Dr. Krauss has received stock or an ownership interest from EpiWatch.
Ilo Leppik, MD	Dr. Leppik has nothing to disclose.
Elinor Ben-Menachem, MD, FAAN	Dr. Ben-Menachem has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Ben-Menachem has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvelle. Dr. Ben-Menachem has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharma. Dr. Ben-Menachem has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Acta Neurologica Scandinvica. The institution of Dr. Ben-Menachem has received research support from zogenic.
Dave F. Clarke, MD	Dr. Clarke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis.
Gregory K. Bergey, MD, FAAN	Dr. Bergey has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics.

��ɫ��

��ɫ��